Clinical Trials Logo

Hypofibrinogenemia clinical trials

View clinical trials related to Hypofibrinogenemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05780125 Completed - Surgery Clinical Trials

Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness

EDIPORE
Start date: March 20, 2023
Phase: Phase 2
Study type: Interventional

Fibrinogen concentrate is produced by different manufacturers using different purification technologies. The products available in Italy are three: RiaSTAP (CSL Behring), FIBRYGA (Octapharma), and FibCLOT (LFB). RiaSTAP and FIBRYGA are sold in 1-gram vials, and FibCLOT - in 1.5-gram vials. A recent in vitro study assessed how these products affected the clot firmness measured by the ROTEM FIBTEM maximum clot firmness (MCF) parameter. In vitro conditions, FibCLOT was verified to be the most efficient in increasing clot firmness. The present study is aimed to assess, in a series of patients undergoing cardiac surgery with cardiopulmonary bypass, the hypothesis that the FibCLOT fibrinogen is superior to the RiaSTAP fibrinogen in increasing the FIBTEM MCF parameter in a clinical model of bleeding (postoperative bleeding after complex cardiac surgery).

NCT ID: NCT02822599 Completed - Hypofibrinogenemia Clinical Trials

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

RiaSTAP
Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.